Skip to content
TrialScanner

NCT07553663

Evaluating the Pharmacokinetics and Safety of Miricorilant

Phase 1CompletedCORTLead

Registry record

Lead sponsor
Corcept Therapeutics
Conditions
Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-alcoholic Fatty Liver Disease (NAFLD)
Primary completion
Sep 22, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07553663 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.